When you talk to your doctor about treatment for chronic myelogenous leukemia (CML), you may hear him say that your goal is to get into remission. If you're like most folks, you've got a general idea ...

Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...

Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid leukemia. This form of cancer was once regarded as very difficult to combat, ...

CML is a cancer of the blood. In people with CML, there is a disruption in the process that governs the normal life cycle of white blood cells. As a result, too many white blood cells develop. CML is ...

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

December 12, 2006 (Orlando) — A new aurora kinase inhibitor is the first to show clinical activity in a population of treatment-resistant leukemia patients with a poor prognosis. The new Merck and ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

Here, doctors share the number-one sign of leukemia in adults over 50, plus other key symptoms like night sweats, weight loss ...